UNITED STATES
SECURITY AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q /A
Amendment No. 1
(MARK ONE)
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2016
or
o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 333-170315
AngioSoma Inc.
(Exact name of registrant as specified in its charter)
Nevada |
| 27-3480481 |
(State or other jurisdiction of Incorporation or organization) |
| (I.R.S. Employer Identification Number) |
|
|
|
14001 Walden Rd., Suite 600 |
| 77356 |
(Address of principal executive offices) |
| (Zip code) |
Registrant’s telephone number, including area code: 832-781-8521
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o | Smaller reporting company | þ |
| (Do not check is smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)
Yes o No þ
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of September 13, 2016, 31,520,667 shares of common stock are issued and outstanding.
EXPLANATORY NOTE
The purpose of this Amendment No. 1 to the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016 (“Form 10-Q”) is to submit Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 consists of the Interactive Data Files from the Registrant’s Form 10-Q for the quarterly period ended June 30, 2016, filed with the Securities and Exchange Commission on September 13, 2016.
ITEM 6. EXHIBITS
3.1 | Articles of Incorporation (1) |
3.2 | Bylaws (2) |
14.1 | Code of Ethics (3) |
31.1 | Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer and principal financial and account officer. (4) |
32.1 | Section 1350 Certification of principal executive officer and principal financial accounting officer. (4) |
101 | XBRL data files of Financial Statement and Notes contained in this Quarterly Report on Form 10-Q. (5) |
__________
(1) | Incorporated by reference to our Definitive Proxy Statement on Schedule 14A filed on April 8, 2015. |
(2) | Incorporated by reference to our Form 10-K/A Amendment No. 1 for the year ended September 30, 2015 filed on January 22, 2016. |
(3) | Incorporated by reference to our Form S-1 filed with the Securities and Exchange Commission on November 3, 2010. |
(4) | Previously filed or furnished herewith. |
(5) | In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AngioSoma Inc. |
|
|
Date: September 15, 2016 | BY: /s/ Alex Blankenship |
| Alex Blankenship |
| Chief Executive Officer, President, Secretary, Treasurer, Principal Executive Officer, Principal Finance and Accounting Officer and Sole Director |
- 2 -
Document and Entity Information - shares |
2 Months Ended | |
---|---|---|
Jun. 30, 2016 |
Sep. 13, 2016 |
|
Document And Entity Information | ||
Entity Registrant Name | AngioSoma, Inc. | |
Entity Central Index Key | 0001502152 | |
Document Type | 10-Q | |
Trading Symbol | SOAN | |
Document Period End Date | Jun. 30, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --09-30 | |
Entity a Well-known Seasoned Issuer | No | |
Entity a Voluntary Filer | No | |
Entity's Reporting Status Current | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 31,520,667 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2016 |
CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) |
Jun. 30, 2016
USD ($)
$ / shares
shares
|
---|---|
Statement of Financial Position [Abstract] | |
Evaluated property, accumulated depletion | $ | $ 116,673 |
Evaluated property, accumulated impairment | $ | 128,358 |
Current portion of convertible notes payable, discount | $ | 143,438 |
Noncurrent portion of convertible notes payable, discount | $ | $ 376,773 |
Common stock, par value (in dollars per share) | $ / shares | $ 0.0010 |
Common stock, authorized | 480,000,000 |
Common stock, issued | 31,520,667 |
Common stock, outstanding | 31,520,667 |
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.001 |
Preferred stock, authorized | 20,000,000 |
Series A Preferred stock, issued | 5,000,000 |
Series A Preferred stock, outstanding | 5,000,000 |
Series E Preferred stock, issued | 1,000,000 |
Series E Preferred stock, outstanding | 1,000,000 |
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
2 Months Ended |
---|---|
Jun. 30, 2016
USD ($)
$ / shares
shares
| |
Income Statement [Abstract] | |
OIL AND GAS SALES, net | $ 1,665 |
OPERATING EXPENSES | |
Lease operating expense | 108 |
Depletion, depreciation and amortization | 386 |
Accretion expense | 121 |
General and administrative expenses | 25,292 |
Total operating expenses | 25,907 |
LOSS FROM OPERATIONS | (24,242) |
OTHER INCOME (EXPENSE) | |
Interest expense | (59,676) |
NET LOSS | $ (83,918) |
NET LOSS PER COMMON SHARE - Basic and diluted (in dollars per share) | $ / shares | $ (0.00) |
COMMON SHARES OUTSTANDING - Basic and diluted (in shares) | shares | 18,780,547 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) |
2 Months Ended |
---|---|
Jun. 30, 2016
USD ($)
| |
Consolidated Statements Of Comprehensive Income | |
NET LOSS | $ (83,918) |
Change in fair value of available-for-sale securities | (4,464) |
Comprehensive loss | $ (88,382) |
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - 2 months ended Jun. 30, 2016 - USD ($) |
Common Stock [Member] |
Series A Preferred Stock [Member] |
Series E Preferred Stock [Member] |
Additional Paid-In Capital [Member] |
Accumulated Other Comprehensive Income [Member] |
Accumulated Deficit [Member] |
Total |
---|---|---|---|---|---|---|---|
BALANCE AT BEGINING at Apr. 29, 2016 | $ 10,023 | $ 1,000 | $ 11,023 | ||||
BALANCE AT BEGINING (in shares) at Apr. 29, 2016 | 10,022,543 | 1,000,000 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net loss | (83,918) | (83,918) | |||||
Other comprehensive loss | (4,464) | (4,464) | |||||
Common stock issued for conversion of convertible note payable | $ 1,498 | 5,993 | 7,491 | ||||
Common stock issued for conversion of convertible note payable (in shares) | 1,498,124 | ||||||
Common stock issued for acquisition | $ 20,000 | (401,444) | (381,444) | ||||
Common stock issued for acquisition (in shares) | 20,000,000 | ||||||
Preferred stock issued for intellectual property | $ 2,990,535 | 2,990,535 | |||||
Preferred stock issued for intellectual property (in shares) | 5,000,000 | ||||||
BALANCE AT END at Jun. 30, 2016 | $ 31,521 | $ (395,451) | $ (4,464) | $ (83,918) | $ 2,539,223 | ||
BALANCE AT END (in shares) at Jun. 30, 2016 | 31,520,667 | 5,000,000 | 1,000,000 |
General Organization and Business |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
General Organization and Business | Note 1. General Organization and Business
AngioSoma Inc., a Nevada corporation, is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).
AngioSoma Nevada is developing its lead product, a drug candidate called LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.
The Company incorporated on April 29, 2016. The Companys year-end is September 30.
On June 3, 2016, we entered into a business combination whereby a wholly-owned subsidiary of the Company, AngioSoma Research, Inc., a Texas corporation, (AngioSoma Texas) merged with AngioSoma Research, Inc., a Nevada corporation, (AngioSoma Nevada) with AngioSoma Research Texas surviving as our wholly-owned subsidiary (the Merger) . In connection with the Merger, the Company issued to the holders of outstanding common stock of AngioSoma Nevada 20 million shares of the Companys common stock (Common Stock) and, as a result, immediately following the completion of the Merger, the former equity holders of AngioSoma Nevada owned approximately 66% of the Common Stock and the stockholders of First Titan Corp. immediately prior to the Merger owned approximately 34% of the Common Stock, in each case, on a fully-diluted basis (subject to certain exceptions and adjustments). Also in connection with the Merger, the pre-Merger director and officer of the Company tendered his resignation and the pre-Merger director and officer of AngioSoma Nevada was appointed as the new director and officer of the Company, and our corporate headquarters was moved from Las Vegas, Nevada to Montgomery, Texas. In connection with completion of the Merger, the Company changed its corporate name from First Titan Corp. to AngioSoma, Inc. and its common stock continues to trade on the OTC Markets Group, OTCQB tier under the new trading symbol SOAN.
First Titan Energys oil and gas development activities include the following:
Alabama On May 2, 2012, we acquired a one percent working interest in one well in Little Cedar Creek Field in Alabama. This well was drilled during the fiscal year ended September 30, 2012 and we began receiving revenue during the fiscal year ended September 30, 2013. This well is located in the Little Cedar Field, Alabamas largest producing oil field. This well is currently producing oil and natural gas from one well.
Louisiana On January 3, 2012, we entered into a participation agreement in an oil and gas drilling project in Calcasieu Parish, Louisiana (the Participation Agreement). The South Lake Charles Prospect is located seven miles south of the city of Lake Charles, Louisiana. It is a middle Oligocene age geo-pressured prospect located in the middle and lower hackberry sands. Under the terms of the Participation Agreement, we will participate in the drilling of one well and may participate in the drilling of future wells if it chooses. We will pay 25% of the drilling cost of the first well and will receive 13.59% of the net revenue from the well. We anticipate that our share of the total drilling and completion cost of the initial well, projected to be drilled to approximately 15,500 feet, will be $3.4 million. On August 12, 2013, the Participation Agreement was amended to reduce our working interest to 1.8%. As a result, our share of the drilling cost is expected to be approximately $181,000. The Company has paid $143,264 of its share of the costs of the well to date. We will receive 1.4% of the revenue from this well. The well began being drilled during the year ended September 30, 2014. During the year ended September 30, 2015, before the completion of the well, the well was damaged by a subcontractor working on the well. The operator of the well is in arbitration with the relevant subcontractors for compensation on the damage to the well.
Texas On July 7, 2013, the Company acquired a 30% working interest in the Minns Project located in Waller County, Texas. The project included three producing wells and a salt water disposal well within the Brookshire Field. This well was reworked and deepened during the year ended September 30, 2014. It is currently producing oil from one well. |
Going Concern |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Going Concern | Note 2. Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the period from inception (April 29, 2016) through June 30, 2016, the Company had a net loss of $83,918 and negative cash flow from operating activities of $12,001. As of June 30, 2016, the Company had negative working capital of $648,128. Management does not anticipate having positive cash flow from operations in the near future.
These factors raise a substantial doubt about the Companys ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business.
Management has plans to address the Companys financial situation as follows:
In the near term, management plans to continue to focus on raising the funds necessary to implement the Companys business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Companys financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Companys ability to continue as a going concern.
In the long term, management believes that the Companys projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Companys future growth. However, there can be no assurances that the Companys planned activities will be successful, or that the Company will ultimately attain profitability. The Companys long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations. |
Summary of Significant Accounting Policies |
2 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies | Note 3. Summary of Significant Accounting Policies
Interim Financial Statements
The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. The results of operations for the period from inception (April 29, 2016) through June 30, 2016 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2016.
Consolidated Financial Statements
The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, AngioSoma Research, LLC, First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Credit Risk due to Certain Concentrations
We extend credit, primarily in the form of uncollateralized oil and gas sales through the operators of our working interests, to various companies in the oil and gas industry, which results in a concentration of credit risk. The concentration of credit risk may be affected by changes in economic or other conditions within our industry and may accordingly affect our overall credit risk. However, we believe that the risk of these unsecured receivables is mitigated by the nature of the companies to which we extend credit. For the period from inception (April 29, 2016) through June 30, 2016, two operators accounted for 54% and 46% of our oil and gas sales. Those operators account for 35% and 65% of accounts receivable as of June 30, 2016. We did not recognize any credit losses during the period from inception (April 29, 2016) through June 30, 2016. We have not recognized an allowance for doubtful accounts as of June 30, 2016.
Oil and Gas Properties
The Company follows the full cost method of accounting for its oil and gas properties, whereby all costs incurred in connection with the acquisition, exploration for and development of petroleum and natural gas reserves are capitalized. Such costs include lease acquisition, geological and geophysical activities, rentals on non-producing leases, drilling, completing, and equipping of oil and gas wells and administrative costs directly attributable to those activities and asset retirement costs. Disposition of oil and gas properties are accounted for as a reduction of capitalized costs, with no gain or loss recognized unless such adjustment would significantly alter the relationship between capital costs and proved reserves of oil, in which case the gain or loss is recognized in the statement of operations.
Depletion of capitalized oil and gas properties and estimated future development costs, excluding unproved properties, are based on the units-of-production method based on proved reserves. The company recognized $386 of depletion during the period from inception (April 29, 2016) through June 30, 2016. Net capitalized costs of oil and gas properties, less related deferred taxes, are limited to the lower of unamortized cost or the cost ceiling, defined as the sum of the present value of estimated future net revenues from proved reserves based on unescalated prices discounted at ten percent, plus the cost of properties not being amortized, if any, plus the lower of cost or estimated fair value of unproved properties included in the costs being amortized, if any, less related income taxes. As of June 30, 2016, the Company has oil and gas properties in the amount of $200,575, which are being excluded from amortization because they have not been evaluated to determine whether proved reserves are associated with those properties. Costs in excess of the present value of estimated future net revenues as discussed above are charged to impairment expense. The Company applies the full cost-ceiling test on a quarterly basis on the date of the latest balance sheet presented.
Based on managements review, 100% of the unproved oil and gas properties balance as of June 30, 2016 are expected to be added to amortization during the year ending September 30, 2016. The table below sets forth the cost of unproved properties excluded from the amortization base as of June 30, 2016 and notes the year in which the associated costs were incurred:
Asset retirement costs are recognized when the asset is placed in service, and are included in the amortization base and amortized over proved reserves using the units of production method. Asset retirement costs are estimated by management using existing regulatory requirements and anticipated future inflation rates.
Financial Instruments
The Companys balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.
FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entitys own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2016. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, and accrued expenses. The fair value of the Companys notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
The following table presents assets that were measured and recognized at fair value as of June 30, 2016 and the period then ended on a recurring and nonrecurring basis:
Revenue Recognition
Sales of crude oil are recognized when the delivery to the purchaser has occurred and title has been transferred. This occurs when oil has been delivered to a pipeline or a tank lifting has occurred. Crude oil is priced on the delivery date based upon prevailing prices published by purchasers with certain adjustments related to oil quality and physical location.
Common Stock
The Company records common stock issuances when all of the legal requirements for the issuance of such common stock have been satisfied.
Income Taxes
The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of June 30, 2016.
Earnings (Loss) per Common Share
The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share. The basic earnings (loss) per common share are calculated by dividing the Companys net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Companys net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported.
In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Companys convertible debt is considered anti-dilutive due to the Companys net loss for the period from inception (April 29, 2016) through June30, 2016. As a result, the Company did not have any potentially dilutive common shares for that period. At June 30, 2016, the Company had 32,762,153 potentially issuable shares upon the conversion of convertible notes payable and interest.
Beneficial Conversion Feature
Beneficial conversion feature is a non-detachable conversion feature that is in the money at the commitment date. The Company follows the guidance of ASC Subtopic 470-20 Debt with Conversion and Other Options to evaluate as to whether beneficial conversion feature exists. Pursuant to Section 470-20-30 an embedded beneficial conversion feature recognized separately under paragraph 470-20-25-5 shall be measured initially at its intrinsic value at the commitment date (see paragraphs 470-20-30-9 through 30-12) as the difference between the conversion price (see paragraph 470-20-30-5) and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. When the Company issues a debt or equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the debt or equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Companys common stock and the effective conversion price of the debt or equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the debt or equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the debt or equity security.
Commitments and Contingencies
The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of June 30, 2016.
Recently Issued Accounting Pronouncements
We have reviewed the FASB issued Accounting Standards Update (ASU) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporations reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.
Subsequent events
The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.. |
Acquisition |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Business Combinations [Abstract] | |
Acquisition | Note 4. Acquisition
On June 3, 2016, we entered into a business combination whereby a wholly-owned subsidiary of the Company, AngioSoma Research, Inc., a Texas corporation, (AngioSoma Texas) merged with AngioSoma Research, Inc., a Nevada corporation, (AngioSoma Nevada) with AngioSoma Research Texas surviving as our wholly-owned subsidiary (the Merger) . In connection with the Merger, the Company issued to the holders of outstanding common stock of AngioSoma Nevada 20 million shares of the Companys common stock (Common Stock) and, as a result, immediately following the completion of the Merger, the former equity holders of AngioSoma Nevada owned approximately 66% of the Common Stock and the stockholders of First Titan Corp. immediately prior to the Merger owned approximately 34% of the Common Stock, in each case, on a fully-diluted basis (subject to certain exceptions and adjustments). Also in connection with the Merger, the pre-Merger director and officer of the Company tendered his resignation and the pre-Merger director and officer of AngioSoma Nevada was appointed as the new director and officer of the Company, and our corporate headquarters was moved from Las Vegas, Nevada to Montgomery, Texas. In connection with completion of the Merger, the Company changed its corporate name from First Titan Corp. to AngioSoma, Inc. and its common stock continues to trade on the OTC Markets Group, OTCQB tier under the new trading symbol SOAN.
For accounting purposes, the Merger is treated as a reverse acquisition under generally acceptable accounting principles in the United States (U.S. GAAP) and AngioSoma Nevada is considered the accounting acquirer. Accordingly, AngioSomas historical results of operations will replace the Companys historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Companys financial statements. |
Intellectual Property |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intellectual Property | Note 5. Intellectual Property
On April 29, 2016, an individual contributed certain medical intellectual property to the Company in exchange for 5,000,000 shares of Series A Preferred Stock. The transaction was valued at $2,990,535 based upon the value of the Series A Preferred Stock as determined by a valuation expert. |
Advances Payable to Related Party |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Debt Disclosure [Abstract] | |
Advances Payable to Related Party | Note 6. Advances Payable to Related Party
During the period from inception (April 29, 2016) through June 30, 2016, the Company received non-interest bearing advances from a shareholder of the Company in the amount of $11,000. The advances remained outstanding as of June 30, 2016. |
Advances |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Debt Disclosure [Abstract] | |
Advances | Note 7. Advances
As of June 30, 2016, the Company had non-interest bearing advances payable to a third party of $21,650. These advances are payable on demand. |
Convertible Notes Payable |
2 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | Note 8. Convertible Notes Payable
Convertible notes payable consisted of the following at June 30, 2016:
All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.
Conversions to Common Stock
During period from inception (April 29, 2016) through June 30, 2016, the holders of the Convertible Note Payable dated December 31, 2014 elected to convert accrued interest of $7,491 into 1,498,124 shares of common stock. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement that provided for conversion. |
Stockholders' Equity |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity | Note 9. Stockholders Equity
Common stock issued for reverse acquisition
On June 3, 2016, the Company issued 20,000,000 shares for the reverse acquisition of AngioSoma Nevada. See Note 4.
Common stock issued for conversion of convertible note payable
On June 28, 2016, the Company issued 1,498,124 shares of common stock upon the conversion of accrued interest of $7,491. No gain or loss was recognized on the transaction because it was transacted within the terms of the convertible note payable.
Series A Preferred Stock
On April 29, 2016, an individual contributed certain medical intellectual property to the Company in exchange for 5,000,000 shares of Series A Preferred Stock. The transaction was valued at $2,990,535 based upon the value of the Series A Preferred Stock as determined by a valuation expert. |
Subsequent Events |
2 Months Ended |
---|---|
Jun. 30, 2016 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 10. Subsequent Events
The Company has reviewed subsequent events through the filing of this report and has noted none that require disclosure. |
Summary of Significant Accounting Policies (Policies) |
2 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interim Financial Statements | Interim Financial Statements
The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. The results of operations for the period from inception (April 29, 2016) through June 30, 2016 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2016. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consolidated Financial Statements | Consolidated Financial Statements
The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, AngioSoma Research, LLC, First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Use of Estimates | Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Credit Risk due to Certain Concentrations | Credit Risk due to Certain Concentrations
We extend credit, primarily in the form of uncollateralized oil and gas sales through the operators of our working interests, to various companies in the oil and gas industry, which results in a concentration of credit risk. The concentration of credit risk may be affected by changes in economic or other conditions within our industry and may accordingly affect our overall credit risk. However, we believe that the risk of these unsecured receivables is mitigated by the nature of the companies to which we extend credit. For the period from inception (April 29, 2016) through June 30, 2016, two operators accounted for 54% and 46% of our oil and gas sales. Those operators account for 35% and 65% of accounts receivable as of June 30, 2016. We did not recognize any credit losses during the period from inception (April 29, 2016) through June 30, 2016. We have not recognized an allowance for doubtful accounts as of June 30, 2016. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oil and Gas Properties | Oil and Gas Properties
The Company follows the full cost method of accounting for its oil and gas properties, whereby all costs incurred in connection with the acquisition, exploration for and development of petroleum and natural gas reserves are capitalized. Such costs include lease acquisition, geological and geophysical activities, rentals on non-producing leases, drilling, completing, and equipping of oil and gas wells and administrative costs directly attributable to those activities and asset retirement costs. Disposition of oil and gas properties are accounted for as a reduction of capitalized costs, with no gain or loss recognized unless such adjustment would significantly alter the relationship between capital costs and proved reserves of oil, in which case the gain or loss is recognized in the statement of operations.
Depletion of capitalized oil and gas properties and estimated future development costs, excluding unproved properties, are based on the units-of-production method based on proved reserves. The company recognized $386 of depletion during the period from inception (April 29, 2016) through June 30, 2016. Net capitalized costs of oil and gas properties, less related deferred taxes, are limited to the lower of unamortized cost or the cost ceiling, defined as the sum of the present value of estimated future net revenues from proved reserves based on unescalated prices discounted at ten percent, plus the cost of properties not being amortized, if any, plus the lower of cost or estimated fair value of unproved properties included in the costs being amortized, if any, less related income taxes. As of June 30, 2016, the Company has oil and gas properties in the amount of $200,575, which are being excluded from amortization because they have not been evaluated to determine whether proved reserves are associated with those properties. Costs in excess of the present value of estimated future net revenues as discussed above are charged to impairment expense. The Company applies the full cost-ceiling test on a quarterly basis on the date of the latest balance sheet presented.
Based on managements review, 100% of the unproved oil and gas properties balance as of June 30, 2016 are expected to be added to amortization during the year ending September 30, 2016. The table below sets forth the cost of unproved properties excluded from the amortization base as of June 30, 2016 and notes the year in which the associated costs were incurred:
Asset retirement costs are recognized when the asset is placed in service, and are included in the amortization base and amortized over proved reserves using the units of production method. Asset retirement costs are estimated by management using existing regulatory requirements and anticipated future inflation rates. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments | Financial Instruments
The Companys balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.
FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entitys own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2016. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, and accrued expenses. The fair value of the Companys notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
The following table presents assets that were measured and recognized at fair value as of June 30, 2016 and the period then ended on a recurring and nonrecurring basis:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | Revenue Recognition
Sales of crude oil are recognized when the delivery to the purchaser has occurred and title has been transferred. This occurs when oil has been delivered to a pipeline or a tank lifting has occurred. Crude oil is priced on the delivery date based upon prevailing prices published by purchasers with certain adjustments related to oil quality and physical location. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock | Common Stock
The Company records common stock issuances when all of the legal requirements for the issuance of such common stock have been satisfied. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | Income Taxes
The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of June 30, 2016. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings (Loss) per Common Share | Earnings (Loss) per Common Share
The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share. The basic earnings (loss) per common share are calculated by dividing the Companys net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Companys net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported.
In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Companys convertible debt is considered anti-dilutive due to the Companys net loss for the period from inception (April 29, 2016) through June30, 2016. As a result, the Company did not have any potentially dilutive common shares for that period. At June 30, 2016, the Company had 32,762,153 potentially issuable shares upon the conversion of convertible notes payable and interest. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial Conversion Feature | Beneficial Conversion Feature
Beneficial conversion feature is a non-detachable conversion feature that is in the money at the commitment date. The Company follows the guidance of ASC Subtopic 470-20 Debt with Conversion and Other Options to evaluate as to whether beneficial conversion feature exists. Pursuant to Section 470-20-30 an embedded beneficial conversion feature recognized separately under paragraph 470-20-25-5 shall be measured initially at its intrinsic value at the commitment date (see paragraphs 470-20-30-9 through 30-12) as the difference between the conversion price (see paragraph 470-20-30-5) and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. When the Company issues a debt or equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the debt or equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Companys common stock and the effective conversion price of the debt or equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the debt or equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the debt or equity security. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies | Commitments and Contingencies
The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of June 30, 2016. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements
We have reviewed the FASB issued Accounting Standards Update (ASU) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporations reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent events | Subsequent events
The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR. |
Summary of Significant Accounting Policies (Tables) |
2 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of cost of unproved properties excluded from the amortization base | The table below sets forth the cost of unproved properties excluded from the amortization base as of June 30, 2016 and notes the year in which the associated costs were incurred:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of assets measured and recognized at fair value on a recurring and nonrecurring basis | The following table presents assets that were measured and recognized at fair value as of June 30, 2016 and the period then ended on a recurring and nonrecurring basis:
|
Convertible Notes Payable (Tables) |
2 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of convertible notes payable | Convertible notes payable consisted of the following at June 30, 2016:
|
General Organization and Business (Details Narrative) |
2 Months Ended | ||||
---|---|---|---|---|---|
Jun. 03, 2016
USD ($)
|
Aug. 12, 2013
USD ($)
|
Jul. 07, 2013
Number
|
Jan. 03, 2012
USD ($)
ft²
Number
|
Jun. 30, 2016
USD ($)
|
|
Number of common shares issued for aquisition | $ (381,444) | ||||
First Titan Corp [Member] | |||||
Percentage of common stock owned | 34.00% | ||||
AngioSoma Research Nevada [Member] | |||||
Number of common shares issued for aquisition | $ 20,000,000 | ||||
Percentage of common stock owned | 66.00% | ||||
Waller County, Texas [Member] | Minns Project [Member] | |||||
Number of wells in processs fo drilling | Number | 3 | ||||
Percentage of working interest | 30.00% | ||||
Participation Agreement [Member] | Calcasieu Parish, Louisiana [Member] | |||||
Number of wells in processs fo drilling | Number | 1 | ||||
Percentage of oil and gas production expense | 25.00% | ||||
Percentage of oil and gas revenue | 1.40% | 13.59% | |||
Projected drilling feet | ft² | 15,500 | ||||
Total drilling and completion cost | $ 181,000 | $ 3,400,000 | |||
Percentage of reduce working interest | 1.80% | ||||
Payment of oil and gas cost | $ 143,264 |
Going Concern (Details Narrative) |
2 Months Ended |
---|---|
Jun. 30, 2016
USD ($)
| |
Accounting Policies [Abstract] | |
Net loss | $ (83,918) |
Cash flow from operating activities | (12,001) |
Working capital | $ (648,128) |
Summary of Significant Accounting Policies (Details) - USD ($) |
12 Months Ended | ||||
---|---|---|---|---|---|
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2013 |
Sep. 30, 2012 |
Jun. 30, 2016 |
|
Cost of unproved properties excluded from amortization, period costs: | |||||
Acquisition costs | $ 47,311 | $ 153,264 | |||
Development costs | |||||
Exploration costs | |||||
Total | $ 47,311 | $ 153,264 | |||
Cost of unproved properties excluded from amortization, cumulative costs: | |||||
Acquisition costs | $ 200,575 | ||||
Development costs | |||||
Exploration costs | |||||
Total | $ 200,575 |
Summary of Significant Accounting Policies (Details Narrative) |
2 Months Ended |
---|---|
Jun. 30, 2016
USD ($)
shares
| |
Depletion expense | $ 386 |
Unevaluated properties | $ 200,575 |
Potentially issuable shares | shares | 32,762,153 |
Sales [Member] | Operator One [Member] | |
Concentration risk percentage | 54.00% |
Sales [Member] | Operator Two [Member] | |
Concentration risk percentage | 46.00% |
Accounts Receivable [Member] | Operator One [Member] | |
Concentration risk percentage | 35.00% |
Accounts Receivable [Member] | Operator Two [Member] | |
Concentration risk percentage | 65.00% |
Acquisition (Details Narrative) - USD ($) |
2 Months Ended | |
---|---|---|
Jun. 03, 2016 |
Jun. 30, 2016 |
|
Business Acquisition [Line Items] | ||
Number of common shares issued for aquisition | $ (381,444) | |
First Titan Corp [Member] | ||
Business Acquisition [Line Items] | ||
Percentage of common stock owned | 34.00% | |
AngioSoma Research Nevada [Member] | ||
Business Acquisition [Line Items] | ||
Number of common shares issued for aquisition | $ 20,000,000 | |
Percentage of common stock owned | 66.00% |
Intellectual Property (Details Narrative) - USD ($) |
2 Months Ended | |
---|---|---|
Apr. 29, 2016 |
Jun. 30, 2016 |
|
Value of shares issued for intangible assets | $ 2,990,535 | |
Series A Preferred Stock [Member] | ||
Number of shares issued for intangible assets | 5,000,000 | |
Value of shares issued for intangible assets | $ 2,990,535 | |
Medical Intellectual Property [Member] | Series A Preferred Stock [Member] | ||
Number of shares issued for intangible assets | 5,000,000 | |
Value of shares issued for intangible assets | $ 2,990,535 |
Advances Payable to Related Party (Details Narrative) |
Jun. 30, 2016
USD ($)
|
---|---|
Debt Disclosure [Abstract] | |
Advances payable to related party | $ 11,000 |
Advances (Details Narrative) |
Jun. 30, 2016
USD ($)
|
---|---|
Debt Disclosure [Abstract] | |
Advances payable to third party | $ 21,650 |
Convertible Notes Payable (Details Narrative) |
2 Months Ended |
---|---|
Jun. 30, 2016
USD ($)
shares
| |
Maximum percentage of the outstanding stock of the company upto which holder of the notes can convert the notes into shares of common stock | 4.90% |
10% Convertible Note Payable Due December 31, 2016 [Member] | |
Accrued interest | $ | $ 7,491 |
Number of shares issued | shares | 1,498,124 |
Stockholders' Equity (Details Narrative) - USD ($) |
2 Months Ended | |||
---|---|---|---|---|
Jun. 28, 2016 |
Jun. 03, 2016 |
Apr. 29, 2016 |
Jun. 30, 2016 |
|
Number of common shares issued for aquisition | $ (381,444) | |||
Value of shares issued for intangible assets | 2,990,535 | |||
Series A Preferred Stock [Member] | ||||
Number of common shares issued for aquisition | ||||
Number of shares issued for intangible assets | 5,000,000 | |||
Value of shares issued for intangible assets | $ 2,990,535 | |||
Medical Intellectual Property [Member] | Series A Preferred Stock [Member] | ||||
Number of shares issued for intangible assets | 5,000,000 | |||
Value of shares issued for intangible assets | $ 2,990,535 | |||
AngioSoma Research Nevada [Member] | ||||
Number of common shares issued for aquisition | $ 20,000,000 | |||
Convertible Notes Payable [Member] | ||||
Accrued interest | $ 7,491 | |||
Number of shares issued | 1,498,124 |
&PO=V]R:V)O;VLN>&ULE99;4^(P%(#_2J8OZ[XL-%Q6&7$&H2HS"HQEW>?0
M!LB8)IBD>/GU>U)$#Y)%?8$F;;XD)U]/SZGM/&IS/]/ZGCP54MF.Z49+YU:=
M6LUF2UXP^TNON()[ (S9E-"Y& .(Y3F)?69LA@>9Y=-L,-90Y1)FC&
M0 I "R&2SPF)KK;$K>QW=N<_!&MU[+3;$5]:+Z>+!V:WU._PLCA4._FCZG=U
M-P0O2IN-N=T_;Y72TC@@=W$8[,WYY_+0R*T>;U-SW[L3@7O0ZC =<"ZGK/(O
M4$L#!!0 ( $B2+TE06B>.H $ +$# 8 >&PO=V]R:W-H965T 5IM-;[#SF]\T[>(0QO!IG+>A-Z\^
MG7EA6AOQ+$\2^B!(I[ )?Y!>TCK[_G[W='_0;=E'3_PDPW#_ERA^B,18>FD<
M25]W'LAD%RC<#B=HH)*12*G$EZ:A)*^\Z;3) <62N2]C')I/:Z.
M<)/(E1?X0GX"W9C6#_PNSF"/IHK5O325=2HNH@S85TZS'%Y=):!EDZQVUL-[
M+PB)0%!-(H7UB%3"N$$6R-05LSR$:6)0W4N9+> TXQFN E<''/"Z.MIU$-)"
MYUZJ9PP:N!6V+05W)'*
MBT9DT;0^3JCYL
MSS1Q$E3 &3A)]^]G[(\T[3X1[R6 <[YSC@W'E^*L^M=A+Z4.WMJF&Y;A7NO#
M?10-Z[ULJ^%.'61G_MFJOJVT>>QWT7#H9;6Q16T3,4*2J*WJ+BP+V_;4EX4Z
MZJ;NY%,?#,>VK?H_*]FH\S*DX=3P7._V>FR(RB*ZU&WJ5G9#K;J@E]ME^$#O
M5YR,$(OX6COO\W@F[_"J''@'O[CIA+;DA,Z?;#R %M&!;Y_=[2CI_?M9
M$PFM"^%7'YMTI5+B<%@>R/I*JW]02P,$% @ 2)(O24\:&PBC 0 L0,
M !@ !X;"]W;W)K
W4XL^U%B/F,&'2Y+I)OFJ23P+I-R8SYNNG(&>#
M$Z#;<#X-JM0@;9S;DEVNP'T6!O\)+XN>MO!(=
60$FSVY("X,%>(AI+4,/QSM7A,*:58N FN0'SMA03;HSC:
MYZ0;[@T-"2_X"29-HKEK0L?X,VEMF&VU4NEX>PL?9!BF#66G#A/- 7'V-9)@
MDF52
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MZVW\F"K),#"B@+-6&+1
9,2+
M^M$:/FM;=:
1>2]R#
M=K?3[G2)N(?MSOGQ74+/X5DN9SL\RW7O%<]] \^#X\=S_SYX'CP GKL&GGO'
MC^?N??#<>P \]PP\]X\?S[W[X+F_3SRON,'ZSO8BJ@WT/EBD2?P!?"-?9I1E
M1LF-[?FH<"=A%(,'=2V<-/(P;O8T;!"-@]=W^N-_PCQVY,SN""-Y2V0-SNHU
M1@S +N)8))>^'1?OYF_8FT>,:#_&A>PU6]-0Z194^N2)HE^4<]R;D/GCWV?*P[42+K*NQ10]K^D6=O/@JU/GFBZ#4V
MW=;44SGOO+'I'EU]-^3\Z*J[(>==I7-#I5L(W2=/%$MAF,9%.8A03..BU"7O
M&M(^,(NT(>URTJYR E @JG!"=1
M2/QQDJR4,W8'^6ZW#@VPJUL(@S ($KD@-&PI,.)JQ[]Q/90K(JG9'Z&^1<$J
M3''\?$D#$NL2[ACDNB60 6:5.#4A0(31(S,2I1!'0K['DPEI!&_)D@?59 06'IUZF?&TX,=E1VIUE7
M=MD +NG'B3]U$5L]SO9WMRN[:D-0SB@.$
M+,TD3(I@F1__.(_(T$_X3U*3$1-9K\3>P&)4(L"!U64:!#QFV8OZJ>>1.!ZE
M07KU(I2.S7+D]Z@-S!.
M%DNF60F)A+06.'K#
6'ATXY%:AC]0FJQ"RW-$2C;K
M[PA\9"[G! !&L1>@8D=,X[SX$C_*>V5@%HB?ZFC!7N&W\CX'"S7S[B*:KT F
M:#C#;\75 J-9<\_W<4:N]U_80)/O># "A 6%NK)T^@TB&+;<$WUB1ZR5@RM;%&P B/0J_
M@]U/LXU&/QFKT^!*G2482P8BJ4V617VR+&R4=9*#'605ZM%0;PP#6SIS?U Z
M
0B928
MTV^.-56/)!5C4"K?_HV(G+BT]FQB6>^GA,%0:X7H".:';-1Q\@>72KW=$2\!WZJ]U.^Q_TV&
9R:F/L
M.:V-Z<1((HO5'==B;A' EMY W.%J;J AVJ6+QSP&,8,8'X##B(=0%,\AUX.
MAT@5(9#0X'.R"(B& U'KGJ"CT3';\RRY.&&.;\O0% +>#^>>@[9"B$$W'-#U
M5-29$I1PD0I*G
P@,Y I'&KHS3@*G8
M^5]I:%2KHF8>U'R"D<"-+K";8\(E!5D.&[2G&N8^_X#S6]T7NG\1%J9:FG=I
MN99\L2_7S;V[>3&ZS'89+FPJL(:=A,9J*[ FS7ZJO:RNS++G4BSF>XMDW<&)
MRD;O/.8U Y6H_T! K#V)6ND&EH->2@ER)]N^F #@O?[)L*_V:I>E$
MP &V*KZ=>
2X_QKVBXT]4.TR-KIGW9J1L22G
M/@MX5/P91M_@^??JAL$CL^E9B4 M!;2XQ[NKC8?9UT&_-QID^[J#LC!15&T7
MP2(9J>5M;9VLV+)^IV3'-NS5V[]2,+9^%\DL=-^#VQLGB(.KVP!,]IFWR$8J
M,UK(CLL$D+;F@$,$7I\!FX[7L!GVT2C;B,HP[7,Q[[PH3KYXB1U
D^JB1QX5(T
MP /"\T4026\0QS@-8]?(05QVX691H.Z'4BH]U(Z-HJ:CMW5@7?GH'F)W\'B/
M"$-*E J:Z\%S8A0>J:;6X3+!'O< 7R#;I-L7H>?U* N^HF!!7=ZSBD'2H=U+
MM6Q.(M[Y?DON?;I"[EXR"PYE&)CVW_I*;OI?60TK[Y$%L%V]##1]
O71##M8$I=U:$U'96U ]0UA'8;"]>,@.ETO]J;2Z* -(HYT
M:BDE,ETD+17U%*H?8KL6FB&>O;F1V%/D\V_O%F4:ZPU,Q02F:YMJTZLT,&GV
M05FS#TJ9O;XBY?YF']B=[B6F17R$EIE%J"E-)^>ZNA67R;H&-E!IP8"77&
M6I^Q5EB915EI'%*P.YNP4Q*5X>(F=$@!/-H$F!0UUK+5%:%4;H<4YN.M0HUU
M&+$2PX=&K,:(]52./QOJ"0MJM3'5W%P0*8"GFP 3TD8H;JSDJ^L8Y**\.V=;
MG4!"\!=C*5IA!\9('I%">;[=52W%C*6)-D4^&M^!J>E&.5L90Q-Y:NLA38>C
M+*C,4JZQD",\S/Z)/))^HN8AA%-LD(&PTM&AFF+5LG?/7?2U=MRW#L+^B$R4
MO&N(%MPN.^O1\7G-G36KFD()G*PR/5>]<[9UA@'0@X8@_&*X7 )X?&%
MYHE.9&U@\:?! 9P4>AKQMX:^/C;Z1-<6.GFXY&O:0V(E#&*QK+:1_@Y<%_>]
M1P0MXB,.)C?(<5UN=A26A/:L<8&7O2/$"@8A[B*!:D[!8/)HOH?A%"/8>UNX
M$(&N9]^0#L*%BX'CDC=?3;Q>TF.%BA16J"]?)=A5]C8"@\[5S]..W0M C)K!
M%>-IO8G@@2Y[C8S5:*)%4V O6^PM *PRSGQ6[Q)F0ZYR KA+TD%,)@RINS!(
MNR33"4"W&Y(MT@XL8D[7\IT707Z.XCKUY;8
GXB<^ODY+XXM_]NO=?]?M1OYI)_:U"D'84_E1[WRHXJCWW<\XD \N5F'Z
M?(3NR'>< #.;A1?99Q(]Q'@YIQX.7/SZ5/E>?/I,L+7^?'7AWNGCBK!.K+(8
M*!>^*0Y(
2;@BGZ/(3ZZ)?L'FHM IH1J!5QAEE(9#J2:(=4X)!6#6:<@[
M+DQC,6_>TN2W3\^?2.C-%SC^S;9":U3KV$'%J1(U'Q6K#AB:.0)5O=U+:HCK
MH4)MO[<]DZ5\%CD)]1Y.)J'.-I)&@,4^4I'HG0U66/6^S^40$P1F;[[@OT7Q
M<)6DT8+$MN<-.L$N;8H9:-F*J%*],Z41FF(I,IENK,+=4]1L%4I"G5L%!:!B
M%0J)WOO:"LMH%9@@,*LP\#R^@V.K*8_0QT;?6+-XQT\ K*!K'O]:V=X9Y A0
MXW,MQ-%:'ABE+C&-16""<;AB=')XTNB>4 O
!6\/(K^6!T,V!Y#&8/+Q.I@\IQSVO'A%?/:Q
MR+%4^C,,\MW$9(FI/_J^)&%"[*PSR'9)-RO<,L^T@F (9D.GIG84LHA(82A&
MJ[P*<%DI]+C6:EQC=
'39!+
MKPU-HKV3S0V?,LD+$31 "IO>UJFC-\@=TFC4BD8C"#0:N=-H!)Q&(P<:C50:
MG79#HQT=U?F^")^)@QM,_7$XQ$O*-O^F8R*3=*<'-+UHWE'A';]!W&U*XM=U RF$&Q
MT^HH&\S!]"=T>37YN?+$__HS&@SOQM]$1MV/, ;0P/_;*DG%PPR>DVAIP%NS:)7DP=#+ :0FA]]:!<4\G=:R
M4.K)V?^"9 _U)C/'5SUV#7B._8YXU=.N_ 6CPQO_/720>%&2[QCKP)_S[%G2
MZ_M:\ZC:715.EVT*7$F#&!*^RA2Y,M?7,3 L^2!,J4^#%=_<3WD,/5H_"!A&
MB^4JQ9*R]>P'@P4/AVQ:F.^F[$ZW1KMLCLHV:A<%@YEM=ED;Y?U'E+(IB.(@
M>!:/E7ADO>SQ$HPALXX^^VF5T) D2?E!UJ?GTF\BMJ"A#=L7TT]TXG:5U(
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M2
M*3T .ZHA:8N%=*;1\>!K]EIU0[MO$]IM"NXU7?G! =]Y7C"6FQPKK!I=I^1N
M@&ZV)17QWB< =XQUYN4RR&="$"EUB3W[K:U9O#\RJ:#-3%K+ J61 E#U];A/
M$2WDN:.J)Y)* K52)2.]3O5S$U//T699]?LCG4.US"RT* .E93-BC0-9)H:6
M7 Z]I"'RHR# <<)=R>1Q]0][.LVJHN>_U5>NYJUV5;JSLZMFR(;3C;)H[_1Q
MPVKE9>!(%_P=[I8+
8V';9G@WL4D,XZ-#,_9F=E"T($5<_$(I5
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M#0:S:7_6 S-Z&&\F-LP!@)IK@_61@/?P2,!Y[]OM7?=K]Z9_]6O7N;IAOW
*[
MOF0+18/A$=,OE*=$L_F.1&&]H7ZJ&"HG<>8T5@O.\ZQ]7O&%X>7!+M1*:*RZ
M?Q]X28R$Z=4%31^2S@--DS(T X;K65!_]%JX!^!]6#8W-7(5QZ^N?##85C^=
M3MWHI3?J^^/0'_D>XZ#*>JW5'1^M6UW1F4-'3JD[9]F?L^AP;Y(ML#+?=5R0
MV(O\V?+^\-I@ 9;9H*M=,]#&TL)@IW4IT2O&>+QNC&4*^RIZ3J;%L"S$65
M4R&PN))PN?=LG.^:[@AW87A)5N*-Z596&?J.9*^IG-,XT3'$S;_!LGU"D!=8
M:%O2Q6"XG($@(&S8;G ;4;;!%KS#>WRR;L%E4F=!:T_YOU Z?/*#@,F>#8WS
MRB^B9MX"G3"79C=VP^*"X0$,&41LV48;(5H-I$.%A,$>.\-'=C@F\WO4O+!'
M-H-P9[7 ,$\K2VO1AU-TXB34*;IQ\G[LZ>R\=@C4&D7MVXS:264N,R5.#26V
M;$IRN9